Prospective Study
Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Sep 6, 2016; 5(5): 471-481
Published online Sep 6, 2016. doi: 10.5527/wjn.v5.i5.471
Table 1 Baseline patient characteristics (n = 470), as a function of vitamin D status
All 25(OH)D < 20 ng/mL 25(OH)D 20-29 ng/mL 25(OH)D ≥ 30 ng/mL P n 470 252 (53%) 154 (33%) 64 (14%) Age (yr) 66.1 ± 12.9 65.8 ± 13.1 65.9 ± 11.9 68.1 ± 12.1 0.421 Male sex (%) 309 (66%) 162 (64%) 101 (66%) 46 (72%) 0.303 High blood pressure (%) 444 (95%) 242 (96%) 144 (94%) 58 (91%) 0.072 Dyslipidemia (%) 311 (66%) 168 (68%) 101 (66%) 42 (66%) 0.646 Diabetes mellitus (%) 183 (39%) 114 (45%) 53 (34%) 16 (25%) 0.001 Ischemic heart disease (%) 104 (22%) 60 (24%) 33 (22%) 11 (17%) 0.224 Chronic heart failure (%) 43 (9%) 33 (13%) 7 (5%) 3 (5%) 0.005 Stroke (%) 52 (11%) 30 (12%) 15 (10%) 7 (11%) 0.668 Peripheral arterial disease (%) 93 (20%) 59 (24%) 22 (14%) 12 (19%) 0.117 Stage of CKD (%) 3 (eGFR = 30-59 mL/min per 1.73 m2 ) 221 (47%) 103 (41%) 84 (54%) 34 (53%) 0.002 4 (eGFR = 15-29 mL/min per 1.73 m2 ) 205 (44%) 105 (46%) 64 (42%) 26 (41%) 5 (eGFR < 15 mL/min per 1.73 m2 ) 44 (9%) 34 (13%) 6 (4%) 4 (6%) Etiology of CKD (%) Hypertension 108 (23%) 54 (21%) 40 (26%) 14 (22%) 0.039 Diabetes mellitus 108 (23%) 72 (29%) 29 (19%) 7 (11%) Tubulointerstitial disease 65 (14%) 24 (10%) 25 (16%) 16 (25%) Glomerulonephritis 47 (10%) 26 (10%) 15 (10%) 6 (10%) Unknown/others 142 (30%) 75 (30%) 44 (29%) 20 (32%) Smoking (%)1 Never 231 (53%) 124 (52%) 82 (58%) 25 (44%) 0.494 Ex-smoker 144 (33%) 81 (34%) 44 (31%) 19 (33%) Active 64 (14%) 35 (14%) 16 (11%) 13 (23%) Blood pressure (kPa) Systolic 19.0 ± 2.9 19.3 ± 2.9 18.6 ± 2.8 19.0 ± 3.1 0.085 Diastolic 10.2 ± 1.5 10.2 ± 1.6 10.1 ± 1.4 10.3 ± 1.7 0.617 Pulse pressure (kPa) 8.8 ± 2.5 9.1 ± 2.5 8.5 ± 2.5 8.7 ± 2.5 0.098 Body mass index (kg/m2 ) 28.6 ± 5.1 28.8 ± 5.5 28.6 ± 4.6 27.7 ± 4.4 0.294 Underweight ( ≤ 18.5) 6 (1%) 4 (2%) 1 (1%) 1 (2%) 0.353 Normal (18.6-24.9) 96 (20%) 50 (20%) 30 (19%) 16 (25%) Overweight (25.0-29.9) 210 (45%) 111 (44%) 68 (44%) 31 (48%) Obesity (> 29.9) 158 (34%) 87 (34%) 55 (36%) 16 (25%) Waist (cm) Males 102.2 ± 12.0 102.1 ± 13.0 102.2 ± 10.6 102.4 ± 11.5 0.989 Females 97.8 ± 13.5 98.3 ± 14.7 97.7 ± 12.2 95.7 ± 11.4 0.760 ABPI 1.01 ± 0.21 0.98 ± 0.20 1.04 ± 0.21 1.05 ± 0.22 0.013 Abnormal ABPI2 194 (41%) 100 (41%) 66 (44%) 28 (44%) 0.539 Abnormal Kauppila score3 107 (29%) 52 (27%) 35 (29%) 20 (36%) 0.183 Abnormal Adragao score4 121 (32%) 66 (33%) 38 (30%) 17 (29%) 0.474 Vitamin D supplementation (%) 43 (9%) 16 (6%) 17 (11%) 10 (16%) 0.012 Use of phosphate binders (%) 72 (15%) 47 (19%) 16 (11%) 9 (14%) 0.105 Use of ACEI/ARB (%) 365 (78%) 196 (79%) 121 (82%) 48 (76%) 0.947 Use of diuretic (%) 287 (61%) 173 (70%) 88 (58%) 26 (42%) < 0.001 Use of ESA (%) 124 (26%) 77 (31%) 31 (20%) 16 (25%) 0.015
Table 2 Baseline laboratory values, as a function of vitamin D status
All (n = 470) 25(OH)D < 20 ng/mL (n = 252) 25(OH)D 20-29 ng/mL (n = 154) 25(OH)D ≥ 30 ng/mL (n = 64) P 25-hydroxivitamin D (nmol/L) 52 ± 21 36 ± 9 61 ± 7 90 ± 16 < 0.001 1,25(OH)2 vitamin D (pmol/L) 103 ± 28 97 ± 27 111 ± 28 107 ± 23 < 0.001 Caalb (mmol/L) 2.40 ± 0.20 2.40 ± 0.15 2.42 ± 0.23 2.45 ± 0.23 0.163 P (mmol/L) 1.10 ± 0.26 1.10 ± 0.26 1.10 ± 0.26 1.07 ± 0.26 0.517 iPTH (ng/L)1 91 (85-97) 106 (96-116) 81 (73-91) 64 (55-74) < 0.001 Creatinine (μmol/L) 221 ± 97 239 ± 106 212 ± 88 212 ± 88 0.017 eGFR (MDRD, mL/min per 1.73 m2 ) 29.4 ± 11.5 28.1 ± 11.9 30.8 ± 10.8 30.5 ± 11.1 0.049 Urine protein excretion (g/24 h)1 2 0.592 (0.502-0.697) 0.699 (0.573-0.853) 0.448 (0.321-0.626) 0.448 (0.271-0.742) 0.034 hsCRP (nmol/L)1 36.2 (29.5-39.1) 37.1 (33.3-41.0) 36.2 (31.4-41.0) 32.4 (26.7-39.1) 0.506 Albumin (g/L) 40 ± 5 39 ± 5 41 ± 5 40 ± 5 0.011 Total proteins (g/L) 77 ± 12 77 ± 11 77 ± 13 76 ± 14 0.877 Total cholesterol (mmol/L) 4.7 ± 1.1 4.7 ± 1.1 4.7 ± 1.0 4.8 ± 1.1 0.603 HDL cholesterol (mmol/L) 1.3 ± 0.4 1.3 ± 0.3 1.3 ± 0.4 1.3 ± 0.4 0.973 LDL cholesterol (mmol/L) 2.7 ± 0.9 2.7 ± 0.9 2.7 ± 0.9 2.9 ± 0.8 0.344 Hemoglobin (g/L) 130 ± 16 129 ± 16 132 ± 16 132 ± 18 0.058 Ferritin (pmol/L)1 225 (207-245) 227 (202-252) 216 (187-252) 247 (191-319) 0.635 Transferrin (μmol/L) 3.0 ± 1.2 2.9 ± 1.2 3.0 ± 1.2 3.1 ± 1.3 0.289 Glucose (mmol/L) 6.3 ± 2.2 6.3 ± 2.3 6.4 ± 2.4 5.9 ± 1.5 0.241
Table 3 Adjusted Cox proportional hazards models of patient survival (events = 46)
Model Covariates controlled for Adjusted HR (95%CI) P 0 (Unadjusted) 25-hydroxivitamin D levels (mg/dL) 0.95 (0.91-0.99) 0.009 1 25-hydroxivitamin D levels (mg/dL) + age 0.95 (0.91-0.99) 0.009 2 Model 1 + diabetes mellitus, ischemic heart disease, chronic heart failure 0.96 (0.92-0.99) 0.028 3 Model 1 + peripheral arterial disease, abnormal ABPI1 , phosphorous (mg/dL) 0.95 (0.92-0.99) 0.023 4 Model 1 + DBP (mm Hg), 1,25(OH)2 vitamin D (pg/mL), estimated GFR (mL/min per 1.73 m2 ) 0.96 (0.92-0.99) 0.020 5 Model 1 + vascular calcification [Kauppila score (log), Adragao score (log)], CKD stage 5 0.95 (0.91-1.00) 0.050 6 Model 1 + obesity, hemoglobin (g/L), albumin (g/dL) 0.95 (0.92-0.99) 0.019
Table 4 Multivariate Cox regression analysis in relation to renal end point (events = 156)
HR (95%CI) P value25-hydroxivitamin D (ng/mL) 0.97 (0.95-0.99) 0.004 Age (yr) 0.99 (0.97-1.00) 0.044 Male sex 2.20 (1.47-3.30) < 0.001 Estimated GFR (mL/min per 1.73 m2 ) 0.93 (0.91-0.95) < 0.001 ABPI (mmHg) 0.23 (0.10-0.53) 0.001 Hemoglobin (g/L) 0.84 (0.78-0.94) 0.001
Citation: Molina P, Górriz JL, Molina MD, Beltrán S, Vizcaíno B, Escudero V, Kanter J, Ávila AI, Bover J, Fernández E, Nieto J, Cigarrán S, Gruss E, Fernández-Juárez G, Martínez-Castelao A, Navarro-González JF, Romero R, Pallardó LM. What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? World J Nephrol 2016; 5(5): 471-481
URL: https://www.wjgnet.com/2220-6124/full/v5/i5/471.htm
DOI: https://dx.doi.org/10.5527/wjn.v5.i5.471